Artisan Bio announced an extension of its research collaboration with Takeda which leverages Artisan's genome editing technology. The amended agreement builds on the companies' initial research program established in 2020 with a new research plan that includes gene targets of mutual interest to facilitate Takeda's cell therapy research programs.
"Takeda and Artisan both recognize the potential of engineered next-generation cell therapies to address the critical unmet patient needs not addressed by first generation CAR programs" said Artisan Bio CEO Dr. Ryan Gill. "We are excited to continue our collaboration combining our expertise in genome engineering with Takeda's immuno-oncology expertise to accelerate the development of allogeneic cell therapies."
Under the terms of the agreement, Artisan Bio will receive additional funding to provide its genome editing tools for Takeda to use in the research and development of its cell therapy programs. Takeda will be responsible for the development, manufacturing, and commercialization of any potential resulting cell therapy products.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!